Knight Therapeutics raises 2026 guidance and reports record nine-month revenue
FROM THE WIRE · FINANCE.YAHOO.COM
Knight Therapeutics Achieved nine-month record-high revenues of over $430 million and Adjusted EBITDA1 of over $76 million Raised 2026 guidance to revenues of $560 million to$570 million and Adjusted EBITDA1 of approximately 17.5% of revenues Raised peak annual revenues for…
Read at the source ↗MARKET IMPACTNEUTRAL✦ News Impact agent estimateTone: expected bullishThe raised 2026 guidance is a positive signal for the Canadian company's stock.AI-generated summary
✦ IN BRIEF · AIAI-generated summary
- 01Nine-month revenue exceeded CAD 430 million, a record high.
- 02The 2026 guidance was raised to revenue of CAD 560 to 570 million.
- 03Adjusted EBITDA is expected at about 17.5% of revenue.
NEWS IMPACT AND MARKET REACTIONChange since the story · reference
Impact and summary are estimates by the News Impact AI agent, not financial advice.Open in Markets